Targeting the Nicotinic Cholinergic System to Treat Attention-Deficit/Hyperactivity Disorder: Rationale and Progress to Date Alexandra S. PotterGeoffrey SchaubhutMegan Shipman Leading Article 28 October 2014 Pages: 1103 - 1113
Methamphetamine Psychosis: Epidemiology and Management Suzette Glasner-EdwardsLarissa J. Mooney Therapy in Practice 06 November 2014 Pages: 1115 - 1126
Pharmacologic Therapies for Malignant Glioma: A Guide for Clinicians Riccardo SoffiettiLuca BerteroRoberta Rudà Therapy in Practice 18 November 2014 Pages: 1127 - 1137
Drug-Induced Cerebellar Ataxia: A Systematic Review J. van GaalenF. G. KerstensB. P. C. van de Warrenburg Systematic Review 13 November 2014 Pages: 1139 - 1153
Pharmacological Strategies for the Management of Levodopa-Induced Dyskinesia in Patients with Parkinson’s Disease Eva SchaefferAndrea PilottoDaniela Berg Review Article 24 October 2014 Pages: 1155 - 1184
A Single-Dose Pilot Trial of Intranasal Rapid-Acting Insulin in Apolipoprotein E4 Carriers with Mild–Moderate Alzheimer’s Disease Michael H. RosenbloomTerry R. BarclayLeah R. Hanson Short Communication 06 November 2014 Pages: 1185 - 1189
Health-Related Quality of Life and Functional Outcomes from a Randomized-Withdrawal Study of Long-Term Lisdexamfetamine Dimesylate Treatment in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder Tobias BanaschewskiMats JohnsonDavid R. Coghill Original Research Article Open access 20 August 2014 Pages: 1191 - 1203
Comment on: “Perispinal Etanercept for Post-Stroke Neurological and Cognitive Dysfunction: Scientific Rationale and Current Evidence” David R. Whitlock Letter to the Editor 06 November 2014 Pages: 1205 - 1206
Authors’ Reply to Whitlock: Perispinal Etanercept for Post-Stroke Neurological and Cognitive Dysfunction: Scientific Rationale and Current Evidence Tracey A. IgnatowskiRobert N. SpenglerEdward Tobinick Letter to the Editor Open access 06 November 2014 Pages: 1207 - 1213
